Sanofi shares have been plummeting because of lowering net income, disappointing return on equity and performance in the stock itself.
However, market was overreacting and short-term bullish reversal ought to be considered.
However, market was overreacting and short-term bullish reversal ought to be considered.
Komen:
No development for this stock, bottom appears to be built but there might be no rise in the share price unless market triggers a clear bullish impulse upwards. And the market is now choppy … I’ll be waiting for some good company news that may persuade people to invest in this stock.